Forxiga: Empowering Glycemic Control and Cardiovascular Protection
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 42 | $3.65 | $153.15 (0%) | 🛒 Add to cart |
| 56 | $3.58 | $204.20 $200.51 (2%) | 🛒 Add to cart |
| 70 | $3.56 | $255.25 $248.87 (3%) | 🛒 Add to cart |
| 84 | $3.51 | $306.30 $295.22 (4%) | 🛒 Add to cart |
| 98 | $3.50
Best per pill | $357.35 $342.57 (4%) | 🛒 Add to cart |
Synonyms | |||
Forxiga (dapagliflozin) is a groundbreaking sodium-glucose cotransporter 2 (SGLT2) inhibitor, offering a dual approach to managing type 2 diabetes mellitus. By promoting urinary glucose excretion, it effectively lowers blood glucose levels while providing additional cardiorenal benefits. Its mechanism is independent of insulin, making it a versatile option either as monotherapy or in combination with other antidiabetic agents. Supported by robust clinical evidence, Forxiga represents a significant advancement in diabetes care, aligning with modern treatment goals that extend beyond glycemic control to encompass overall cardiovascular and renal health.
Features
- Active ingredient: dapagliflozin
- Available in 5 mg and 10 mg film-coated tablets
- SGLT2 inhibitor class, promoting glucosuria
- Once-daily oral administration, with or without food
- Manufactured under stringent quality control standards
- Proven efficacy in HbA1c reduction
- Additional indications for heart failure and chronic kidney disease in certain populations
Benefits
- Achieves significant and sustained reductions in HbA1c levels
- Lowers the risk of major adverse cardiovascular events, including hospitalization for heart failure
- Promotes weight loss through caloric excretion via glycosuria
- Demonstrates renal protective effects, slowing the progression of kidney disease
- Provides a low risk of hypoglycemia when used without insulin or sulfonylureas
- Offers a convenient once-daily dosing regimen, enhancing patient adherence
Common use
Forxiga is primarily indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also approved to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease. It may be used as monotherapy or in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycemic control.
Dosage and direction
The recommended starting dose is 5 mg or 10 mg orally once daily, taken with or without food. For heart failure and chronic kidney disease indications, the recommended dose is 10 mg once daily. Dose adjustment is not required based on age, gender, race, or body weight. In patients with renal impairment, Forxiga is not recommended when eGFR is persistently below 25 mL/min/1.73 m² for the diabetes indication, or below 25 mL/min/1.73 m² for the heart failure and chronic kidney disease indications. Tablets should be swallowed whole with a glass of water.
Precautions
Monitor renal function before initiation and periodically thereafter. Assess volume status and correct volume depletion before starting. Consider temporary interruption in situations of reduced oral intake or fluid loss. Monitor for signs and symptoms of urinary tract infections and genital mycotic infections. Evaluate hematocrit; increases may occur. Use with caution in patients at risk for ketoacidosis, including those on a very low carbohydrate diet. Not recommended during the second and third trimesters of pregnancy. Discontinue at least 3 days before scheduled surgery; consider earlier discontinuation if possible.
Contraindications
Hypersensitivity to dapagliflozin or any excipients. Severe renal impairment (eGFR below 25 mL/min/1.73 m²) for the diabetes indication, end-stage renal disease, or patients on dialysis. History of serious hypersensitivity reactions to Forxiga. Diabetic ketoacidosis.
Possible side effect
- Genital mycotic infections
- Urinary tract infections
- Volume depletion-related adverse reactions (e.g., hypotension, dizziness)
- Increased urination
- Dyslipidemia
- Back pain
- Nausea
- Constipation
- Elevated hematocrit
- Ketoacidosis (rare)
- Necrotizing fasciitis of the perineum (Fournier’s gangrene; very rare)
- Hypersensitivity reactions
Drug interaction
No clinically significant interactions with metformin, glimepiride, pioglitazone, sitagliptin, digoxin, warfarin, or oral contraceptives. Concomitant use with diuretics may increase the risk of volume depletion. Insulin and insulin secretagogues may increase the risk of hypoglycemia; dose reduction of these agents may be required. Not expected to interact with CYP450 enzymes.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. Do not take a double dose to make up for a missed dose. Resume the regular dosing schedule the following day.
Overdose
In the event of overdose, contact a poison control center or seek medical attention immediately. Symptoms may include severe volume depletion, hypoglycemia (if taken with other glucose-lowering agents), and electrolyte abnormalities. Treatment should be supportive and focus on correcting volume depletion, hypoglycemia, and electrolyte imbalances. Dialysis is not expected to enhance elimination.
Storage
Store at room temperature (15–30°C or 59–86°F). Keep in the original blister package to protect from moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Do not disregard professional medical advice or delay in seeking it because of something you have read here. Individual patient responses may vary.
Reviews
Clinical trials and real-world evidence consistently demonstrate Forxiga’s efficacy in glycemic control, cardiovascular risk reduction, and renal protection. In the DECLARE-TIMI 58 trial, dapagliflozin showed a significant reduction in cardiovascular death or hospitalization for heart failure. Patients and healthcare providers report appreciable benefits in glucose management, weight reduction, and overall quality of life. Some note the increased frequency of genital infections as a manageable drawback with proper hygiene and monitoring. Overall, it is regarded as a valuable therapeutic option within modern diabetes and cardiorenal management paradigms.